Xeltis Overview

  • Founded

  • 2006

Founded
  • Status

  • Private

  • Employees

  • 42

Employees
  • Latest Deal Type

  • Series D2

  • Latest Deal Amount

  • $18.3M

  • Investors

  • 9

Xeltis General Information

Description

Developer of medical devices designed to provide a restorative approach to cardiovascular therapy. The company's device comprises bioabsorbable heart valves and blood vessels designed to allow Endogenous Tissue Restoration (ETR) which is the natural restoration of the complex body part that gets replaced upon implantation, enabling the patient's body to naturally restore a new blood vessel or heart valve through a therapeutic approach.

Contact Information

Website
www.xeltis.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Primary Office
  • De Lismortel 31
  • 5612 AR Eindhoven
  • Netherlands
+31 040 000 0000

Xeltis Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Xeltis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Later Stage VC (Series D2) 04-Nov-2022 $18.3M 00000 000.00 Completed Generating Revenue
12. Secondary Transaction - Private 26-May-2022 00000 Completed Generating Revenue
11. Accelerator/Incubator 21-Dec-2021 000.00 00000 Completed Generating Revenue
10. Later Stage VC 22-Nov-2021 000.00 00000 Completed Generating Revenue
9. Later Stage VC (Series D) 05-Sep-2019 000.00 00000 000.00 Completed Clinical Trials - General
8. Later Stage VC (Series C) 15-Nov-2017 000.00 00000 Completed Clinical Trials - General
7. Later Stage VC (Series B) 27-Nov-2015 000.00 000.00 000.00 Completed Clinical Trials - General
6. Later Stage VC (Series B) 08-Dec-2014 000.00 000.00 00000 Completed Clinical Trials - General
5. Later Stage VC (Series A) 15-Oct-2013 $5.5M $14.2M 000.00 Completed Clinical Trials - General
4. Later Stage VC 08-May-2012 $1.72M $8.71M 000.00 Completed Startup
To view Xeltis’s complete valuation and funding history, request access »

Xeltis Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series D2 Preferred 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series D 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Preferred C1 shares 000,000 00.000000 000.00 000.00 00 000.00 00.000
Preferred B shares 000,000 00.000000 000.00 000.00 00 000.00 0.000
Preferred B shares 000,000 00.000000 000.00 000.00 00 000.00 00.000
Preferred B shares 000,000 00.000000 000.00 000.00 00 000.00 0.000
Preferred A Shares 000,000 00.000000 000.00 000.00 00 000.00 0.000
Ordinary shares 00,000 00.000000 000.00 000.00 00 000.00 0.000
Ordinary shares 109,300 $0.982874 $22.11 $22.11 1x $22.11 1.53%
Ordinary shares 137,600 $0.982874 $21.84 $21.84 1x $21.84 1.92%
To view Xeltis’s complete cap table history, request access »

Xeltis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of medical devices designed to provide a restorative approach to cardiovascular therapy. The company's device
Therapeutic Devices
Eindhoven, Netherlands
42 As of 2022
00000
00.00 0000-00-00
00000000000 00000

000000

r sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut lab
00000000 0000000
Irvine, CA
00000 As of 0000
000
000000000 000

00 000

t, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
0000000 000000000
Singapore, Singapore
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Xeltis Competitors (6)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Edwards Lifesciences Corporation Irvine, CA 00000 000 000000000 000
00 00000000 Corporation Singapore, Singapore 000.00 000000000 000.00
000000000000 Private Equity-Backed Puteaux, France 000 000.00 000000000000
000000000 Corporate Backed or Acquired Berlin, Germany 0000 000000&0
00000000 Formerly VC-backed Durham, NC 000 00000 000000000 00000
To view Xeltis’s complete competitors history, request access »

Xeltis Patents

  • 105

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 12

    Granted

  • 9

    Pending

  • 000

    Expiring in next 12 mo

Xeltis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4110200-A1 Medical device for anastomosis Pending 27-Feb-2020 000000000
US-20210267599-A1 Medical device for anastomosis Pending 27-Feb-2020 000000000 0
EP-4076286-A1 Multi-layered electrospun heart valve leaflets Pending 20-Dec-2019 0000000000
US-20230010851-A1 Multi-layered electrospun heart valve leaflets Pending 20-Dec-2019 0000000000
EP-3989881-A1 Electrospun heart valves Pending 27-Jun-2019 A61F2/2415
To view Xeltis’s complete patent history, request access »

Xeltis Executive Team (33)

Name Title Board Seat Contact Info
Eliane Schutte Chief Executive Officer
Alexander Goemans Chief Financial Officer
Martin Cox Ph.D Co-Founder & Chief Technology Officer
Laura Monti Head of Communications
Mark La Meir Ph.D Advisor
You’re viewing 5 of 33 executive team members. Get the full list »

Xeltis Board Members (12)

Name Representing Role Since
Christian Wenger Ph.D Self Board Member 000 0000
Clemens Van Blitterswijk Ph.D EQT Life Sciences Board Member 000 0000
Diego Braguglia Ph.D VI Partners Board Member 000 0000
George Fazio Xeltis Chairman 000 0000
Michael Colson Xeltis Scientific Advisory Board & Chairman 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Xeltis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Xeltis Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
China Grand Pharmaceutical and Healthcare Holdings Corporation Minority 000 0000 000000 0
EIC Accelerator Accelerator/Incubator Minority 000 0000 000000 0
European Investment Bank Investment Bank Minority 000 0000 000000 0
Ysios Capital Venture Capital Minority 000 0000 000000 0
EQT Life Sciences Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial